StreetInsider.com News Articles

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

Thu, 11 Jun 2026 08:00:00 -0400

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demonstrate a favorable safety profile
All patients with TP53 or RAS pathway mutations achieved a complete response, showcasing the activity of the iadademstat combination across genomically defined adverse-risk subgroups and its potential in these populations
In FLT3-mutated refractory-relapsed patients (FRIDA trial), iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%

MADRID and CAMBRIDGE, Mass., June 11,

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

Thu, 11 Jun 2026 08:00:00 -0400

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demonstrate a favorable safety profile
All patients with TP53 or RAS pathway mutations achieved a complete response, showcasing the activity of the iadademstat combination across genomically defined adverse-risk subgroups and its potential in these populations
In FLT3-mutated refractory-relapsed patients (FRIDA trial), iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%

MADRID and CAMBRIDGE, Mass., June 11,

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

Thu, 11 Jun 2026 08:00:00 -0400

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demonstrate a favorable safety profile
All patients with TP53 or RAS pathway mutations achieved a complete response, showcasing the activity of the iadademstat combination across genomically defined adverse-risk subgroups and its potential in these populations
In FLT3-mutated refractory-relapsed patients (FRIDA trial), iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%

MADRID and CAMBRIDGE, Mass., June 11,

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

Thu, 11 Jun 2026 08:00:00 -0400

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demonstrate a favorable safety profile
All patients with TP53 or RAS pathway mutations achieved a complete response, showcasing the activity of the iadademstat combination across genomically defined adverse-risk subgroups and its potential in these populations
In FLT3-mutated refractory-relapsed patients (FRIDA trial), iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%

MADRID and CAMBRIDGE, Mass., June 11,

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

Thu, 11 Jun 2026 08:00:00 -0400

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demonstrate a favorable safety profile
All patients with TP53 or RAS pathway mutations achieved a complete response, showcasing the activity of the iadademstat combination across genomically defined adverse-risk subgroups and its potential in these populations
In FLT3-mutated refractory-relapsed patients (FRIDA trial), iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%

MADRID and CAMBRIDGE, Mass., June 11,

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

Thu, 11 Jun 2026 08:00:00 -0400

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demonstrate a favorable safety profile
All patients with TP53 or RAS pathway mutations achieved a complete response, showcasing the activity of the iadademstat combination across genomically defined adverse-risk subgroups and its potential in these populations
In FLT3-mutated refractory-relapsed patients (FRIDA trial), iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%

MADRID and CAMBRIDGE, Mass., June 11,

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

Thu, 11 Jun 2026 08:00:00 -0400

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demonstrate a favorable safety profile
All patients with TP53 or RAS pathway mutations achieved a complete response, showcasing the activity of the iadademstat combination across genomically defined adverse-risk subgroups and its potential in these populations
In FLT3-mutated refractory-relapsed patients (FRIDA trial), iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%

MADRID and CAMBRIDGE, Mass., June 11,

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

Thu, 11 Jun 2026 08:00:00 -0400

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demonstrate a favorable safety profile
All patients with TP53 or RAS pathway mutations achieved a complete response, showcasing the activity of the iadademstat combination across genomically defined adverse-risk subgroups and its potential in these populations
In FLT3-mutated refractory-relapsed patients (FRIDA trial), iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%

MADRID and CAMBRIDGE, Mass., June 11,

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

Thu, 11 Jun 2026 08:00:00 -0400

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demonstrate a favorable safety profile
All patients with TP53 or RAS pathway mutations achieved a complete response, showcasing the activity of the iadademstat combination across genomically defined adverse-risk subgroups and its potential in these populations
In FLT3-mutated refractory-relapsed patients (FRIDA trial), iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%

MADRID and CAMBRIDGE, Mass., June 11,

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

Thu, 11 Jun 2026 08:00:00 -0400

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demonstrate a favorable safety profile
All patients with TP53 or RAS pathway mutations achieved a complete response, showcasing the activity of the iadademstat combination across genomically defined adverse-risk subgroups and its potential in these populations
In FLT3-mutated refractory-relapsed patients (FRIDA trial), iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%

MADRID and CAMBRIDGE, Mass., June 11,

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

Thu, 11 Jun 2026 08:00:00 -0400

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demonstrate a favorable safety profile
All patients with TP53 or RAS pathway mutations achieved a complete response, showcasing the activity of the iadademstat combination across genomically defined adverse-risk subgroups and its potential in these populations
In FLT3-mutated refractory-relapsed patients (FRIDA trial), iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%

MADRID and CAMBRIDGE, Mass., June 11,

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

Thu, 11 Jun 2026 08:00:00 -0400

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demonstrate a favorable safety profile
All patients with TP53 or RAS pathway mutations achieved a complete response, showcasing the activity of the iadademstat combination across genomically defined adverse-risk subgroups and its potential in these populations
In FLT3-mutated refractory-relapsed patients (FRIDA trial), iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%

MADRID and CAMBRIDGE, Mass., June 11,

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

Thu, 11 Jun 2026 08:00:00 -0400

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demonstrate a favorable safety profile
All patients with TP53 or RAS pathway mutations achieved a complete response, showcasing the activity of the iadademstat combination across genomically defined adverse-risk subgroups and its potential in these populations
In FLT3-mutated refractory-relapsed patients (FRIDA trial), iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%

MADRID and CAMBRIDGE, Mass., June 11,

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

Thu, 11 Jun 2026 08:00:00 -0400

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demonstrate a favorable safety profile
All patients with TP53 or RAS pathway mutations achieved a complete response, showcasing the activity of the iadademstat combination across genomically defined adverse-risk subgroups and its potential in these populations
In FLT3-mutated refractory-relapsed patients (FRIDA trial), iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%

MADRID and CAMBRIDGE, Mass., June 11,

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

Thu, 11 Jun 2026 08:00:00 -0400

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demonstrate a favorable safety profile
All patients with TP53 or RAS pathway mutations achieved a complete response, showcasing the activity of the iadademstat combination across genomically defined adverse-risk subgroups and its potential in these populations
In FLT3-mutated refractory-relapsed patients (FRIDA trial), iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%

MADRID and CAMBRIDGE, Mass., June 11,

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

Thu, 11 Jun 2026 08:00:00 -0400

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demonstrate a favorable safety profile
All patients with TP53 or RAS pathway mutations achieved a complete response, showcasing the activity of the iadademstat combination across genomically defined adverse-risk subgroups and its potential in these populations
In FLT3-mutated refractory-relapsed patients (FRIDA trial), iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%

MADRID and CAMBRIDGE, Mass., June 11,

Freedom Broker Starts Orion Marine Group (ORN) at Buy

Tue, 02 Jun 2026 09:19:14 -0400

Freedom Broker initiates coverage on Orion Marine Group (NYSE: ORN) with a Buy rating and a price target of $16.40.

For an analyst ratings summary and ratings history on Orion Marine Group click here. For more ratings news on Orion Marine Group click here.

Shares of Orion Marine Group closed at $13.83 yesterday.

ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia

Tue, 02 Jun 2026 08:00:00 -0400

MADRID and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the first patient has been enrolled in IDEAL, its Phase II study evaluating iadademstat in patients with essential thrombocythemia (ET).

IDEAL (IaDademstat treatment for EssentiAL thrombocythemia) is a multicenter, single-arm Phase II study being conducted in Spain in adult patients with ET who are resistant or intolerant to hydroxyurea. The study is designed to evaluate the safety, tolerability and clinical activity of iadademstat, including

ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia

Tue, 02 Jun 2026 08:00:00 -0400

ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia

Tue, 02 Jun 2026 08:00:00 -0400

ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia

Tue, 02 Jun 2026 08:00:00 -0400

ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia

Tue, 02 Jun 2026 08:00:00 -0400

ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia

Tue, 02 Jun 2026 08:00:00 -0400

ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia

Tue, 02 Jun 2026 08:00:00 -0400

ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia

Tue, 02 Jun 2026 08:00:00 -0400